TABLE 2

CCM compared with IENF morphology in control subjects and diabetic patients stratified into different clinical severities of neuropathy according to NDS

Control subjectsNo neuropathyMildModerateSevere
CNFD (no/mm2)*43.20 ± 5.0529.05 ± 3.0722.95 ± 2.39§22.59 ± 4.05§20.13 ± 3.14§
IENFD (no/mm)*11.21 ± 0.847.72 ± 1.285.56 ± 0.86§5.84 ± 0.94§2.54 ± 0.76§
CNBD (no/mm2)*27.39 ± 3.318.10 ± 1.807.91 ± 1.70§7.71 ± 2.24§5.55 ± 2.19§
IENFBD (no/mm2)139.66 ± 23.4257.55 ± 14.4139.92 ± 10.53§35.48 ± 10.81§13.47 ± 5.79§
CNFL (mm/mm2)6.14 ± 1.224.59 ± 0.923.87 ± 0.623.64 ± 0.563.69 ± 0.44
IENFL (μm)42.10 ± 4.3138.00 ± 3.3231.47 ± 2.4629.59 ± 4.5322.61 ± 7.12§
  • Data are means±SE in diabetic patients and control subjects. Statistically significant difference using ANOVA:

  • * P < 0.001;

  • P < 0.01;

  • P < 0.05.

  • § Post hoc results significantly different from control subjects.

  • Post hoc results significantly different from the group with no neuropathy.